AU712606B2 - Combined use of interleukin-10 and cyclosporin for immunosuppression therapy - Google Patents

Combined use of interleukin-10 and cyclosporin for immunosuppression therapy Download PDF

Info

Publication number
AU712606B2
AU712606B2 AU68422/96A AU6842296A AU712606B2 AU 712606 B2 AU712606 B2 AU 712606B2 AU 68422/96 A AU68422/96 A AU 68422/96A AU 6842296 A AU6842296 A AU 6842296A AU 712606 B2 AU712606 B2 AU 712606B2
Authority
AU
Australia
Prior art keywords
interleukin
medicament
individual
cyclosporin
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU68422/96A
Other languages
English (en)
Other versions
AU6842296A (en
Inventor
Waleed Tadmori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU6842296A publication Critical patent/AU6842296A/en
Application granted granted Critical
Publication of AU712606B2 publication Critical patent/AU712606B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU68422/96A 1995-08-09 1996-08-06 Combined use of interleukin-10 and cyclosporin for immunosuppression therapy Ceased AU712606B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US205795P 1995-08-09 1995-08-09
US60/002057 1995-08-09
US61995896A 1996-03-20 1996-03-20
US08/619958 1996-03-20
PCT/US1996/012538 WO1997005896A1 (en) 1995-08-09 1996-08-06 Combined use of interleukin-10 and cyclosporin for immunosuppression therapy

Publications (2)

Publication Number Publication Date
AU6842296A AU6842296A (en) 1997-03-05
AU712606B2 true AU712606B2 (en) 1999-11-11

Family

ID=26669861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68422/96A Ceased AU712606B2 (en) 1995-08-09 1996-08-06 Combined use of interleukin-10 and cyclosporin for immunosuppression therapy

Country Status (5)

Country Link
EP (1) EP0845994A1 (ja)
JP (1) JPH11510806A (ja)
AU (1) AU712606B2 (ja)
CA (1) CA2228379A1 (ja)
WO (1) WO1997005896A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030730A1 (en) * 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
EP1000626A1 (en) * 1998-09-18 2000-05-17 Applied Research Systems ARS Holding N.V. Chemokine receptor antagonist and cyclosporin in combined therapy
JP3135532B2 (ja) 1998-09-29 2001-02-19 松下電送システム株式会社 ネットワークファクシミリ装置
US6577712B2 (en) 2000-04-07 2003-06-10 Telefonaktiebolaget Lm Ericsson (Publ) Distributed voice mail system
AU2002952492A0 (en) * 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
EP3062889A2 (en) 2013-11-01 2016-09-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008606A1 (en) * 1992-10-01 1994-04-28 Schering Corporation Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
WO1994017773A2 (en) * 1993-02-01 1994-08-18 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008606A1 (en) * 1992-10-01 1994-04-28 Schering Corporation Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
WO1994017773A2 (en) * 1993-02-01 1994-08-18 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10

Also Published As

Publication number Publication date
AU6842296A (en) 1997-03-05
JPH11510806A (ja) 1999-09-21
CA2228379A1 (en) 1997-02-20
EP0845994A1 (en) 1998-06-10
WO1997005896A1 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
CA2087525C (en) Adoptive immunotherapy with interleukin-7
US9301979B2 (en) Method for attenuating immune response using mesenchymal stem cells and cytokines
EP2931877B1 (en) Methods modulating immunoregulatory effect of stem cells
US6165785A (en) Bone marrow cultures for developing suppressor and stimulator cells for research and therapeutic applications
US11872250B2 (en) Methods for inducing an immune response by administering activated mesenchymal stem cells
CA2253803A1 (en) Use of interleukin-10 to produce a population of suppressor cells
Mastino et al. Combination therapy with thymosin α1 potentiates the anti‐tumor activity of interleukin‐2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice
US20090142317A1 (en) Process for reducing effects of graft versus host disease using ex vivo expanded cd4+cd25+ regulatory t cells
Ramírez et al. Induction of resistance to active experimental allergic encephalomyelitis by myelin basic protein‐specific Th2 cell lines generated in the presence of glucocorticoids and IL‐4
WO1993017698A1 (en) Use of interleukin-10 to suppress graft-vs.-host disease
Chung et al. Importance of interleukin-7 in the development of experimental graft-versus-host disease
AU712606B2 (en) Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
US6022536A (en) Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
Keever et al. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Kaur et al. Zoledronic acid mediated differential activation of NK cells in different organs of WT and Rag2-/-mice; stark differences between the bone marrow and gingivae
EP3307298B1 (en) Multi-peptide composition
KR101488224B1 (ko) 면역학적 질병의 치료를 위한 티모신 알파 1의 용도
MXPA98001091A (en) Combined use of interleukin-10 and cyclosporine for immunosupres therapy
EP0561927B1 (en) Pharmaceutical compositions for the treatment of b-cell malignancies
Wei et al. Lymphokine-activated killer cell regulation of T-cell-mediated immunity to Candida albicans
Frankel et al. Immunotherapy of acute myeloid leukemia
Degauque et al. TIM-1 PATHWAY CONSTITUTE A NEW “FIRST SIGNAL PATHWAY” FOR T CELL.
Mouse Increased Antitumor Effects Using IL-2 with
Kloosterman Graft-versus-leukemia: applicable in the treatment of leukemia with bone marrow transplantation?: preclinical studies in rat models relevant for human acute leukemia
Chung Roles of IL-7 in T cell development and mature T lymphocytes

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired